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Abstract
Background: Genetic as well as epigenetic alterations are a hallmark of both epithelial and haematological
malignancies. High throughput screens are required to identify epigenetic markers that can be useful for diagnostic
and prognostic purposes across malignancies.
Results: Here we report for the first time the use of the MIRA assay (methylated CpG island recovery assay) in
combination with genome-wide CpG island arrays to identify epigenetic molecular markers in childhood acute
lymphoblastic leukemia (ALL) on a genome-wide scale. We identified 30 genes demonstrating methylation
frequencies of ≥25% in childhood ALL, nine genes showed significantly different methylation frequencies in B vs T-
ALL. For majority of the genes expression could be restored in methylated leukemia lines after treatment with 5-
azaDC. Forty-four percent of the genes represent targets of the polycomb complex. In chronic myeloid leukemia
(CML) two of the genes, (TFAP2A and EBF2), demonstrated increased methylation in blast crisis compared to
chronic phase (P < 0.05). Furthermore hypermethylation of an autophagy related gene ATG16L2 was associated
with poorer prognosis in terms of molecular response to Imatinib treatment. Lastly we demonstrated that ten of
these genes were also frequently methylated in common epithelial cancers.
Conclusion: In summary we have identified a large number of genes showing frequent methylation in childhood
ALL, methylation status of two of these genes is associated with advanced disease in CML and methylation status
of another gene is associated with prognosis. In addition a subset of these genes may act as epigenetic markers
across hematological malignancies as well as common epithelial cancers.
Background
The role of aberrant DNA methylation in the develop-
ment of cancer is well recognized and documented.
Tumor suppressor gene (TSG) inactivation by promoter
region CpG island hypermethylation occurs in almost all
cancer types and is an important mechanism of gene
silencing in cancer. Unlike genetic changes in cancer,
epigenetic changes are potentially reversible. Epigenetic
therapy is a rapidly expanding field and a number of
drugs that alter the epigenetic profiles of cancer cells
are already in clinical trails. Two hypomethylating
agents, 5-azacitidine (Vidaza) and 5-aza-2’-deoxycytidine
(Decitabine) are currently in use and are approved
therapies for myelodysplastic syndrome [1,2].
RASSF1A TSG is a classic example of a gene that is
frequently methylated in the majority of adult and child-
hood cancers including epithelial and blood borne can-
cers [3]. The RASSF1 family of genes now includes 10
members (RASSF1-10). We have recently described an
epigenetic profile of the RASSF1-10 genes in childhood
acute lymphoblastic leukemia (ALL) [4]. Our novel find-
ings indicate that RASSF6 and RASSF10 are frequently
and specifically methylated in ALL in contrast to
RASSF1A which is frequently methylated in epithelial
cancers including lung, breast and kidney cancer but
shows low frequency of methylation in childhood ALL.
In addition we have demonstrated that methylation fre-
quencies differ between B and T-ALL. Whilst RASSF6 is
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half (41%) of T-ALL. RASSF10 methylation frequency
shows the opposite trend (16% in B-ALL vs 88% in T-
ALL). Using a chromosome 3 Not1 array hybridization
approach, we recently identified a number of genes fre-
quently methylated in acute lymphoblastic leukemia [5].
We have now used a recently developed high through-
put approach, methylated CpG island recovery assay
(MIRA) in combination with genome-wide CpG island
arrays to identify epigenetic molecular markers in child-
hood ALL on a genome-wide scale. MIRA (methylated-
CpG island recovery assay) is based on the high affinity
of the methyl-CpG binding protein complex MBD2/
MBD3L1 to methylated DNA [6-8]. MIRA assay has
several advantages for use as a tool for comprehensive
analysis of DNA methylation patterns, for example it
does not depend on having specific methylation-sensi-
tive restriction sites in the target sequence, it does not
depend on use of antibodies against 5-methylcytosine,
and the ease of preparation of the recombinant GST
tagged MBD2 and MBD3L1.
Results
Identification of methylated genes in childhood ALL on a
genome-wide based platform
We used the sensitive MIRA method in combination
with genome-wide CpG island arrays to identify fre-
quently methylated genes in childhood ALL. A total of
five T-ALL samples were selected for analysis using the
MIRA assay followed by methylation analysis using a
Agilent, Human CpG Island Chip on chip 244 k array.
The five selected samples were all males to avoid sex
based variation and ranged in age at diagnosis from 5.37
to 12.62 years, there were also no reported transloca-
tions in the samples to avoid specific translocation
derived methylation. Age matched peripheral blood lym-
phocytes from normal healthy individuals were used as
controls in the assay.
The Agilent array is advertised with 237,220 probes
covering 27,800 CpG Islands. A series of criteria were
decided upon to reduce the number of results to a
selection of gene-associated CpG islands that would be
assayed for hypermethylation. The total combined data
set for the five primary samples contained 199,416 CpG
island probes covering 14,020 genes. The first level of
data filtering involved removal of all array probes that
only showed methylation (≥ 3f o l de n r i c h m e n to ft h e
methylated fraction in leukemia samples versus control
samples) in 0, 1 or 2 out of the five samples analysed,
this removed a total of 190,112 probes. The remaining
9304 probes covered 3061 genes, 43 hypothetical pro-
teins, 31 chromosomal loci, 127 predicted open reading
frames, 1728 chromosomal regions and 25 microRNAs.
M a n yo ft h eC p Gi s l a n d sw e r er e p r e s e n t e db y2o r
more probes and therefore is an over representation of
the number of CpG Islands. To further enrich the
results for true positive results that would result in iden-
tification of novel hypermethylated genes, all probes not
labelled by Agilent as ‘promoter’ were removed. This
removed all probes labelled as ‘divergent promoter’,
‘downstream’ and ‘inside’ leaving 2465 probes. Following
this all remaining hypothetical proteins, chromosomal
loci, predicted open reading frames, chromosomal
regions and microRNAs were removed, leaving only
known genes. This left 2022 probes covering 1086
genes. The final step to enrich the data for genes show-
ing only the highest level of methylation involved
removal of all genes which only had a single methylated
probe labelled as ‘promoter’. This resulted in a final list
of 398 genes. Lastly functional annotation was carried
out to determine likely roles in tumorigenesis. Based on
this functional annotation candidate genes were selected
from this final short list and methylation status of their
CpG island’s were investigated. A total of 54 genes, and
62 associated CpG islands (due to multiple isoforms)
were selected for analysis (Figure 1).
Validation of gene methylation in ALL samples
We undertook COBRA (combined bisulfite restriction
analysis) analysis to confirm and extend the methylation
profile of the above genes in a series of B (n = 52) and T
(n = 12) -childhood acute lymphoblastic leukemia samples
(Figure 2) and in a series of leukemia cell lines (n = 12)
(see Additional file 1). We used DNA from age matched
normal healthy blood lymphocytes and bone marrow (n =
10) as controls. Where possible COBRA primers were
designed to encompass the transcription start site within
the CpG island or to within 500bp of the transcription
start site. BstUI and TaqI digest was used for digestion of
COBRA PCR products. Amongst the 54 genes analysed 30
(56%) genes demonstrated frequent methylation (≥ 25%)
in primary B or T ALL or both subtypes as well as leuke-
mia cell lines, with the exception of FAT1, DUSP4 and
POU4F1 that demonstrated lower methylation frequency
in leukemia cell lines compared to primary ALL samples
(Table 1). Two further genes showed methylation fre-
quency of 23% and are included in table 1. The majority of
the above genes (n = 29) were unmethylated in DNA from
control peripheral blood lymphocytes and bone marrow
samples, 2 genes (EBF2, HLA-F) demonstrated some
methylation in 1/10 control samples and one gene
(MYO10) showed methylation in 1/8 control samples.
Nine genes demonstrated differential methylation that was
statistically significant in B vs T-ALL (P < 0.05). Five genes
were significantly more methylated in B-ALL compared to
T-ALL (BARHL2, CYP1B1, FAT1, PTGS2, TSHZ3), whilst
four genes showed more methylation in T compared to B-
ALL (BMP2, MYO10, NR4A2, TCF2). Future studies using
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ential methylation patterns seen above. Another 6 (TAC1,
HMX2, HLA-G, VSNL1, PAX7, PAX9) genes demonstrated
frequent methylation in leukemia cell lines but were also
frequently methylated in DNA from healthy bone marrow
and a further 2 genes showed cancer specific methylation
from analysis of leukemia cell lines and healthy bone mar-
row and blood DNA but showed either no or very low fre-
quency of methylation in primary ALL samples (TNFAIP1,
TLR2). Whilst 14 genes showed no or very low frequency
of methylation in leukemia cell lines, hence these were not
analysed any further (see Additional file 2).
Cloning and direct sequencing of bisulfite modified DNA
To assess the extent of CpG island methylation within
the genes showing cancer specific methylation, bisulfite
modified DNA from primary ALL samples as well as
blood lymphocytes and bone marrow DNA from age
matched control samples was cloned and sequenced
(Figure 3). As seen in figure 3 healthy control bone mar-
row DNA samples show either no or very low level of
methylation across the CpG dinucleotides in contrast to
primary leukemia samples which show methylation
index (MI) values ranging from highly methylated sam-
ples with MI of 62-97%, followed by samples showing
less extensive methylation across the CG dinucleotides
and samples that were classified as unmethylated.
Gene expression and methylation status
We demonstrated that genes listed in Table 1 (our posi-
tive genes) were expressed in control/normal bone mar-
row (Table 1; Figure 4). Leukemia cell lines were treated
with 5-aza-2’-deoxycytidine (5azaDC) with or without
Trichostatin A (TSA). We assayed expression of 26 of
the 32 genes in leukemia cell lines before and after
5azaDC with or without TSA. All 26 genes showed
restoration or upregulation of gene expression following
the above treatment in methylated leukemia cell lines,
whilst unmethylated cell lines showed similar expression
levels before and after treatment.
Functional pathway analysis of methylated genes
The resulting short-list of genes (n = 398) was functionally
annotated using the DAVID bioinformatics tools [9].
Functional analysis revealed that by far the majority of the
genes were involved in regulation of transcription includ-
ing homeobox genes and transcription factors (Figure 5,
Additional file 3). Since transcription factors and homeo-
box genes are known targets of the repressive polycomb
complex in embryonic stem cells, we compared the above
short list of genes with the list of genes marked as poly-
comb targets in human ES cells [10]. Of the 398 genes
identified by MIRA, 45% were found to be polycomb tar-
gets, whilst amongst the validated genes shown to be regu-
lated by promoter region methylation 44% were polycomb
Figure 1 Candidate gene selection. This schematic details the criteria used in the microarray data analysis for the selection of the short list of
398 genes. The short list, only contains genes which had two or more probes labelled as ‘promoter’ which were methyled in at least three of
the five primary samples analysed, this list does not contain any microRNAs or unidentified genes/chromosomal regions.
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tosis, DNA repair, protein processing/activity, cell migra-
tion, cell-cell signalling, regulation of cell cycle/cell
differentiation and proliferation.
From the available clinical and genetic/cytogenetic data
in this cohort of ALL samples we did not find any asso-
ciations with gene methylation. This is likely due to the
limited clinical-pathological data available for these sam-
ples. Hence we looked at another leukemia subtype in
order to determine if gene methylation was related to
any clinical-pathological features, see below for analysis
in chronic myeloid leukemia.
Gene methylation analysis in chronic myeloid leukemia
Unlike ALL, chronic myeloid leukemia (CML) has dis-
tinct disease progression stages. CML progresses from
chronic phase to advance stage disease which includes a
period of biological and clinical acceleration known as
the accelerated phase and blast crisis [11]. We wanted
to determine if our frequently methylated genes in ALL
were also methylated in CML and if they played a role
in CML biology. We analysed a cohort of CML patient
DNA consisting of 55 samples from chronic phase CML
(CP-CML) patients and 8 samples from blast crisis
patients (BC), 5 of these CP and BC-CML were matched
Figure 2 Methylation analysis in B and T-ALL. Representative combined bisulfite restriction analysis (COBRA) results for primary T-ALL and B-
ALL samples and control bone marrow. No methylation was detected in any of the control bone marrow samples. U = undigested PCR
product, B = BstUI digested PCR product. The samples labelled with * correspond to those ALL samples for which methylation was assessed by
cloning and sequencing.
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disease. We demonstrated that only ATG16L2 showed
frequent methylation in CP-CML samples (69%), whilst
the rest of the genes were either unmethylated or
demonstrated methylation frequencies below 20% in
CP-CML patients. Hence ATG16L2 gene is frequently
hypermethylated in both lymphoid and myeloid malig-
nancies. In BC-CML samples 4 genes demonstrated fre-
quencies of >25%, including ATG16L2 (63%). Amongst
the remaining 3 genes, TFAP2A (63%) and EBF2 (57%),
demonstrated statistically significant methylation in BC
vs CP-CML (P < 0.05), whilst TRCP4 was more fre-
quently methylated in BC (50%) compared to CB-CML
( 1 8 % )s a m p l e sb u ti td i dn o tr e a c hs t a t i s t i c a ls i g n i f i c a n t
(P= 0.06) (Table 2). Four out of the 5 matched CP/BC
patient samples demonstrated increased methylation in
t h eD N Af r o mB Cp h a s ea sc o m p a r e dt ot h ec h r o n i c
p h a s eD N As a m p l ef r o mt h es a m ep a t i e n t ,i n c l u d i n g
methylation of the TFAP2A, EBF2 and TRCP4 genes.
One matched patient sample became methylation posi-
tive for 10 additional genes on the transition from CP to
BC.
Table 1 Summary of the promoter hypermethylation frequencies and expression analysis of candidate genes in ALL.
Gene Cell lines T-ALL (%) B-ALL (%) PB/BM controls Expression upregulation after 5azaDC
ARHGAP20 6/10 4/12 (33) 33/51 (65) 0/8 YES
ATG16L2 3/7 5/12 (42) 14/52 (27) 0/8 ND
BARHL2† 5/6 3/12 (25) 39/51 (77) 0/9 YES
BMP2† 6/7 7/12 (58) 2/52 (4) 0/8 YES
CDC14B 5/7 4/12 (33) 21/48 (44) 0/9 YES
CYP1B1† 5/6 5/12 (42) 40/52 (77) 0/10 YES
DUSP4 1/6 3/12 (25) 13/52 (25) 0/6 ND
EBF2 5/6 10/12 (83) 49/52 (94) 1/10 YES
EYA2 5/7 3/12 (25) 15/47 (32) 0/10 YES
FAT1† 1/6 3/12 (25) 34/52 (65) 0/10 YES
FOXF2 4/6 3/12 (25) 15/52 (29) 0/9 YES
GPR123 5/7 4/12 (33) 10/48 (21) 0/9 YES
HLA-F 4/6 4/12 (33) 7/52 (14) 1/10 ND
KNDC1 4/7 1/12 (8) 9/40 (23) 0/9 YES
MYO10† 6/8 6/12 (50) 8/51 (16) 1/8 YES
NKX2-1 5/6 5/12 (42) 32/51 (63) 0/9 YES
N2RE1 6/6 4/12 (33) 19/49 (39) 0/8 YES
NR4A2† 3/7 6/12 (50) 5/51 (10) 0/9 ND
PAX2 6/7 2/10 (20) 15/34 (44) 0/9 YES
PAX6 3/6 6/12 (50) 35/52 (67) 0/10 YES
POU4F1 1/6 5/12 (42) 22/51 (43) 0/8 YES
PRDM12 6/6 6/12 (50) 30/45 (67) 0/9 YES
PTGS2† 4/6 6/12 (50) 48/52 (92) 0/10 YES
SALL3 5/6 4/12 (33) 25/52 (48) 0/9 YES
SSPN 7/9 4/12 (33) 32/52 (62) 0/8 YES
TCF2† 5/6 6/12 (50) 5/52 (10) 0/10 YES
TFAP2A 5/6 5/11 (46) 33/49 (67) 0/10 YES
TFAP2C 2/6 10/12 (83) 43/50 (86) 0/10 YES
TP53I11 3/6 3/12 (25) 8/52 (15) 0/9 ND
TRPC4 5/5 9/12 (75) 48/52 (92) 0/10 YES
TSHZ3† 4/6 0/12 (0) 16/52 (31) 0/10 ND
UBE2C 3/6 2/12 (17) 12/52 (23) 0/10 YES
The table summarises the genes showing a methylation frequency of 25% or above (with the exception of UBE2C and KNDC1) in either T or B-ALL or both, that
were unmethylated or showed much lower frequency of methylation in control blood/bone marrow DNA. Also indicated are the genes showing upregulated
expression in methylated leukemia cell lines (but were not upregulated in unmethylated cell lines) after 5-azaDC treatment (’YES’ in the expression upregulation
after 5-azaDC column). PB; peripheral blood lymphocytes from healthy donors. BM; bone marrow DNA from healthy donors. ND; not determined. †; significantly
differential methylation in T-ALL vs B-ALL.
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nib treatment, patients in whom ATG16L2 was methy-
lated at baseline had an inferior chance of achieving
MMR at 12 or 18 months, compared with the cases
which were unmethylated at baseline. At 12 months
only 1 of 14 methylated samples (at 18 months 3 of 12)
demonstrated a significant molecular response, whilst
amongst the 13 unmethylated cases 7 patients (at 18
months 10 of 13) demonstrated molecular response to
imatinib therapy (p = 0.013 and 0.017 at 12 and 18
months respectively). The other genes methylation pat-
tern at baseline did not predict the MMR or CCR (com-
plete cytogenetic response) rates at 12, 18 or 24 months.
Gene methylation analysis in common epithelial cancers
To determine if the frequently methylated genes in ALL
samples could also be target of methylation in common
epithelial cancers, we analysed 58 tumor cell lines
Figure 3 Methylation assessed by sequencing. Representative results of cloning and sequencing of ten genes. COBRA PCR products were
cloned into PGem T-easy vector and colonies were picked and inserts sequenced. Each line is representative of an individual allele. Each circle
represents a single CpG dinucleotide, filled circles represent a methylated CpG dinucleotide whereas clear circles represent an unmethylated CpG
dinucleotide. The MI was calculated as a percentage using the equation; number of CpG dinucleotides methylated/total number of CpG
dinucleotides sequenced x 100. Sequencing of the DNA from control bone marrow shows no or very infrequent methylation, with MIs all below
3.5%. For each gene two samples for which COBRA analysis detected hypermethylation and two for which it did not were sequenced. The
figure shows control bone marrow and two methylated samples for each gene. The sequencing results correlate with the COBRA detected
methylation.
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= 9), kidney (n = 12), prostate (n = 5) and glioma (n =
8) for methylation. Ten genes (BARHL2, EBF2, GPR123,
NR2E1, PAX6, POU4F1, SALL3, TCF2, TFAP2A,
TP53I11) demonstrated methylation frequency of 50%
or above in three or more tumor types (Table 3, see
Additional file 4). Whilst further nine genes showed
methylation frequency of 50% or above in at least one
tumor type (ATG16L2, CYP1B1, FOXF2, NKX2-1,
NR4A2, PAX2, PRDM12, TRPC4, TSHZ3). There were
four genes (CDC14B, FAT1, KNDC1, UBE2C)t h a t
demonstrated no or very low level methylation across all
epithelial tumor cell lines analysed.
Discussion
We have combined the use of genome-wide CpG island
arrays with a novel and sensitive method, the methy-
lated-CpG island recovery assay (MIRA) to identify fre-
quently methylated genes in acute lymphoblastic
leukemia and other cancers. Global profiling of a small
number (n = 5) of samples yielded a large number of
methylation targets that were validated in a large cohort
of clinical samples. Hence the MIRA-based CpG island
microarray platform proved to be both efficient and
effective. We identified and validated 30 genes that were
methylated in 25% or more of ALL samples and 2 genes
that were methylated at a frequency of 23%. Amongst
Figure 4 Re-expression of Methylated genes. Representative examples of leukemia cell line expression data. Expression from cell line RNA
samples before demethylation treatment are labelled ‘-’ and after demethylation treatment ‘+’. Methylated cell lines are labelled with a ‘*’,
expression of these genes in methylated cell lines before treatment could not be detected, expression in the same cell lines was detected after
demethylation treatment. In unmethylated cell lines expression of these genes was detected before and after demethylation treatment to similar
levels.
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gets in cancer, whilst the remaining genes had been
shown to undergo methylation in other cancers but this
is the first report for methylation in ALL. The validated
genes fell into several major functional categories,
including transcription factors (TFAP2A, TFAP2C,
EBF2, TCF2, PAX6, PAX2, FOXF2), cell cycle control
(CDC14B, UBE2C), phosphatases (EYA2, DUSP4), trans-
forming growth factor-beta (TGFB) superfamily (BMP2).
G protein-coupled receptor (GPR123), p53 gene target
(TP53I11), homeobox (TSHZ3, NKX2-1, BARHL2,
POU4F1), enzymes (PTGS2), ion channels (TRPC4), cad-
herin superfamily (FAT1), Zinc finger (PRDM12),
nuclear receptor subfamily (NR2E1, NR4A2), ras associa-
tion domain containing proteins (MYO10, ARHGAP20,
SSPN). Forty-four percent of the validated genes (and
45% of the short list) were targets of the polycomb
complex in embryonic stem cells. This percentage is
similar to what has been reported in other cancers
including lung, breast, colorectal cancer and follicular
lymphoma[7,12-14]. Our data provides further evidence
that polycomb group proteins have an impact on the
epigenetic programming of gene expression in a wide
range of cancers.
Amongst the validated genes, three genes have been
shown to undergo genetic inactivation events in sub
types of leukemia and proposed to act as tumor sup-
pressor genes. GPR123 and KNDC1 have recently been
shown to be mutated in acute myeloid leukemia by
using whole-genome sequencing methodology [15],
whilst PRDM12 is located in a minimal commonly
deleted region in chronic myeloid leukemia[16].
A recent large-scale genome-wide study to identify
genes methylated in adult ALL employing different high
throughput approaches (MCA/RDA and MCA/array)
validated 15 genes as showing frequent methylation in
ALL (GIPC2, RSPO1, MAGI1, CAST1, ADCY5, HSPA4L,
OCLN, EFNA5, MSX2, GFPT2, GNA14, SALL1, MYO5B,
ZNF382, MN1) [17]. In our initial MIRA assay, we also
identified 9 of the above 15 genes as frequent targets of
methylation in childhood ALL, we did not analyze them
any further since they had already been identified and
validated in the Kuang et al study [17].
Figure 5 DAVID functional annotation. The table shows the results of using the online DAVID functional clustering and annotation program
to cluster the short list of 398 genes in to functional groups and pathways. The analysis revealed that the majority of genes cluster as being
involved in transcription, with smaller number of genes involved in functions such as apoptosis, DNA repair, cell cycle progression and cell
signalling.
Table 2 Genes showing differential methylation between
chronic phase (CP) and blast crisis (BC) chronic myeloid
leukemia (CML)
GENE CP BC
ATG16L2 34/49 (69%) 5/8 (63%)
TFAP2A 3/53 (6%) 5/8 (63%)
EBF2 6/52 (11.5%) 4/7 (57%)
TRCP4 10/55 (18%) 4/8 (50%)
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tive neoplasm arising at the level of a pluripotent stem
cell and consistently associated with the BCR-ABL1
fusion gene. CML most commonly manifests in a
chronic phase of the disease that progresses to advanced
stage disease (blast crisis) that is resistance to therapy
[11]. Hence it is important to understand biological
events involved in CML disease progression. We investi-
gated the methylation status of the above genes (fre-
quently methylated genes that were identified using the
MIRA assay and validated in ALL samples) in a cohort
of CML chronic phase and CML blast crisis samples.
This led to the identification of two genes (TFAP2A,
EBF2) that showed a significant increase in methylation
in CML-BC compared to CML-CP samples. We further
determined that in paired samples from the same
patient, BC samples showed methylation of multiple
genes (including the above 2 genes) whilst the corre-
sponding CP samples were mostly unmethylated. Hence
we have identified genes that are likely to play a role in
CML disease progression. TFAP2A, a sequence specific
DNA binding transcription factor has been demon-
strated to be frequently methylated in large B-cell lym-
phoma, renal cell carcinoma and breast cancer [18-20].
TFAP2A has been shown to act as a tumor suppressor
gene and plays an important role in cancer cell chemo-
sensitivity. In breast cancer cells it has been demon-
strated that expression of TFAP2A increased the
chemosensitivity of cancer cells by sensitizing cells to
undergo apoptosis upon chemotherapy[20]. Methylated
breast cancer cell lines treated with 5-aza-2’-deoxycyti-
dine induced reexpression of TFAP2A, resulted in apop-
tosis induction, increased chemosensitivity, decreased
colony formation and loss of tumorigenesis upon che-
motherapy. Amongst the 5 matched paired DNA sam-
ples (CML-CP and CML-BC from the same patient),
TFAP2A was unmethylated in all 5 CML-CP samples
but was methylated in 3 out of the 5 corresponding
CML-BC samples. Hence TFAP2A may play an impor-
tant role in CML-BC samples that become resistant to
chemotherapy.
We also demonstrated that patients with methylation
of ATG16L2 (ATG16 autophagy related 16-like 2), an
autophagy related gene, had a significantly decreased
rate of major molecular response (MMR, defined as a
BCR-ABL: ABL transcript ratio of 0.1% or less) at 12
and 18 months of imatinib treatment in comparison
with patients with unmethylated ATG16L2 gene (p =
0.013 and 0.017 at 12 and 18 months respectively).
Other bona fide autophagy genes including Beclin 1
have been shown to act as tumor suppressor genes in
cancer. Beclin 1 which is required for autophagy induc-
tion is monoallelically deleted in a high percentage of
human breast, ovarian and prostate cancers, and its
expression suppresses the tumorigenicity of human can-
cer cell lines [21-24]. It likely acts as a haploinsufficient
tumor suppressor gene. Beclin 1 heterozygous deficient
mice have decreased autophagy and spontaneously
develop tumors [22]. Beclin 1 forms complexes with a
range of proteins including UVRAG and Bif; these two
proteins may also act as tumor suppressors [25,26].
UVRAG is frequently deleted (monoallelically) in colon
cancers and overexpression leads to suppression of cell
proliferation and tumorigenicity in human colon cancer
cells [25]. Whilst deletion of Bif in mice results in the
development of spontaneous tumors [26]. Recently
ATG16L1 (ATG16 autophagy related 16-like 1) has
been shown to be a bona fide autophagy protein [27].
Another autophagy inducing gene DAPK-1 is frequently
Table 3 Summary of the promoter hypermethylation
frequencies in epithelial cancer cell lines.
Gene Colorectal LUNG BREAST KIDNEY GLIOMA Prostate
ATG16L2 0/9 2/13 1/9 7/10 1/6 0/5
BARHL2* 4/4 3/9 0/3 4/4 ND 3/5
BMP2 4/9 2/14 3/9 0/11 2/7 1/5
CDC14B 0/9 0/14 0/8 0/11 0/7 0/5
CYP1B1 7/9 2/14 1/9 3/5 1/7 2/5
EBF2* 7/9 9/13 4/9 7/10 0/7 0/4
EYA2 2/5 1/11 1/9 1/8 2/6 1/5
FAT1 0/9 1/14 0/9 0/11 0/6 0/5
FOXF2 6/10 0/14 2/9 7/12 3/7 1/5
GPR123* 5/6 5/13 5/9 6/12 1/7 2/5
HLA-F 5/9 8/14 0/9 3/12 1/7 1/5
KNDC1 0/9 0/11 0/9 0/11 1/7 1/5
NKX2-1 3/8 0/12 0/1 2/4 0/1 1/4
NR2E1* 8/9 5/14 5/8 9/11 2/6 4/4
NR4A2 0/9 2/13 0/9 2/12 0/7 4/5
PAX2 3/5 3/10 1/6 1/9 0/5 0/5
PAX6* 6/8 11/12 8/9 7/11 3/7 ND
POU4F1* 6/7 6/13 4/8 7/9 5/7 3/5
PRDM12 3/4 0/4 0/0 6/6 0/0 ND
PTGS2 3/9 1/14 1/9 1/12 1/7 2/5
SALL3* 8/8 6/12 6/8 8/8 5/7 3/5
TCF2* 5/9 8/12 5/9 0/12 5/7 2/5
TFAP2A* 5/9 9/14 2/9 5/7 7/8 1/5
TFAP2C 0/8 3/13 0/9 2/11 1/6 0/5
TP53I11* 2/9 3/13 5/9 8/12 4/7 2/5
TRPC4 8/9 5/14 5/9 4/11 1/7 1/5
TSHZ3 6/7 4/13 3/7 2/11 0/7 ND
UBE2C 0/9 0/14 0/9 0/8 0/6 0/4
The table summarises all of the genes assessed for hypermethylation across
cell lines from six epithelial cancers. The symbol * indicates genes showing
methylation frequency of 50% or above in 3 or more epithelial cancer cell
lines.
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strates tumor and metastasis suppressor properties [28].
Future studies should be aimed at analyzing a larger ser-
ies of CML samples for ATG16L2 epigenetic inactivation
and follow-up clinical parameters and at understanding
the role it may play in CML development.
It would be very useful to identify epigenetic markers
that could be utilized across several malignancies, to
this end we determined the methylation status of the
frequently methylated genes identified in ALL in six
commonly occurring epithelial cancers (lung, breast, col-
orectal, kidney, brain and prostate). Ten genes
(BARHL2, EBF2, GPR123, NR2E1, PAX6, POU4F1,
SALL3, TCF2, TFAP2A, TP53I11) demonstrated methy-
lation frequencies of 50% or higher in 3 or more epithe-
lial cancers. Although our data is from methylation
analysis of epithelial tumor cell lines, one would expect
that some if not many of the above genes showing 50%
or higher methylation frequency in tumor cell lines
would also show frequent methylation in primary
tumors. Our preliminary data for transcription factor
EBF2 suggests that this indeed is the case (EBF2 is
methylated in >25% of lung and breast tumors, data not
shown). In addition, PAX6 methylation has previously
been observed to occur frequently in colorectal and
other cancers, EYA2 is methylated in colorectal cancer,
NKX2-1 is methylated in thyroid cancer, SALL3 is
methylated in hepatocellular carcinoma, TCF2 in ovar-
ian cancer and TFAP2A is methylated in large B-cell
lymphoma, breast and kidney cancers [18-20,29-33]. We
carried out a limited analysis of DNA from normal/con-
trol epithelial tissues (brain, breast and kidney), these
were found to be unmethylated for the genes that were
frequently methylated in the corresponding cancers.
Conclusion
In summary, we have identified and validated a large
number of frequently methylated genes in ALL. In
chronic myeloid leukemia epigenetic inactivation of 2 of
these genes is associated with advanced disease and the
hypermethylation of another gene is associated with
poorer prognosis in CML patients. In addition a large
number of these genes may also be frequently methy-
lated in common epithelial cancers. Future studies of
this group of genes may provide insights into pathogen-
esis of leukemia and other cancers and the identified
methylation targets could be developed into molecular
markers for early detection or therapeutic intervention
across various cancers.
Methods
Patient samples
Twelve leukemia cell lines (DND-41, CCRF-CEM
(CEM), U937, Jurkat (JKT), TALL-1, NALM1, NALM6,
NALM16, NALM17, THP-1, SUP-T1 and MOLT-4)
and 64 primary childhood ALL comprising 52 B-cell
ALL (B-ALL) and 12 T-cell ALL (T-ALL) were analyzed.
Characteristics of the ALL samples have been described
previously and see additional file 5[4,5]. In addition
BCR-ABL positive CML samples consisting of 55
chronic phase and 8 blast crisis samples (including 5
matched CP and BC samples from the same patient)
were also analyzed. DNA from a total of 10 normal per-
ipheral blood lymphocytes and normal bone marrow
(BM, AMS Biotechnology) sample were used as controls.
All DNA samples from patients were obtained with
informed consent and followed institutional guidelines.
Nine colorectal cancer cell lines (174T, DLD1,
HCT116, HT29, LOVO, LS411, SW48, SW60, SW480),
fourteen Lung cancer cell lines (A549, H1155, H1299,
H1395, H1437, H157, H187, H1648, H1792, H187,
H1993, H2171, H 2122, H460), nine breast cancer cell
lines (HCC1143, HCC1395, HCC1419, HCC1437,
HCC1806, HTB29, MCF7, T47D, MDA-MB-231), seven
Glioma cell lines (A172, H4, Hs683, T17, U87, U343,
U373), twelve Renal cell carcinoma cell lines (768-O,
CAKI, KTCL 26, KTCL 140, RCC4, SKRC18, SKRC39,
SKRC45, SKRC47, SKRC54, UMRC2, UMRC3) and five
Prostate cancer cell lines (22Rv1, DU-145, LNCaP, PC3
and VCap) were used in the Epithelial cancer cell line
methylation panel. The collection of epithelial cancer
cell lines have been described in our previous
publications.
Imatinib response criteria for CML
Response to imatinib treatment was defined convention-
ally [34]: complete cytogenetic response (CCR) = no Ph
+ metaphases among at least 20 bone marrow meta-
phases or a BCR-ABL/ABL ratio of 1% or less; Major
molecular response (MMR) = a BCR-ABL/ABL ratio of
0.1% or less.
Detection of DNA methylation changes by MIRA-assisted
microarray platforms
Genomic DNA was fragmented by sonication and MIRA
binding reaction was set up on 200 ng of sonicated
DNA as described previously [8]. The fraction repre-
senting the methylated DNA was collected from the
binding reaction by Ni-NTA magnetic beads (Promega,
Madison, WI) and washed 3 times with a 700-mM
NaCl-containing buffer. Magnetic beads carrying the
isolated fraction were picked up in 200 μlo fT Eb u f f e r ,
mixed with one volume of phenol/chloroform and vor-
texed extensively. Magnetic beads were extracted by a
magnet and the released methylated DNA fraction con-
taining supernatant was ethanol precipitated after
separation of the two phases in a microfuge. Isolated
fraction was blunt-ended with T4 DNA polymerase
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was ligated onto the ends. Amplicons were created by
LM-PCR. Labeling and array hybridization on human
CpG island microarray platform (Agilent Technologies)
were performed as described [8]. MIRA-enriched con-
trol and MIRA-enriched ALL amplicons were hybridized
onto the CpG microarray for detection of ALL-specific
methylation changes. Microarray slides were scanned
using an Axon GenePix 4000b scanner and images wee
quantified by GenePix Pro 6 software.
Gene selection
The short list of 398 genes was generated as described
in results section, also see figure 1.
Methylation analysis
Bisulfite modification of DNA was performed as
described previously [4]. The methylation status of all
the CpG islands were determined by combined bisulfite
restriction analysis (COBRA), semi-nested primers were
designed to amplify regions of the CpG islands close to
or overlapping the transcription start sites from bisulfite
modified DNA (see additional file 6 for primer
sequences). For enzymatic methylation detection ten
microlitres of COBRA PCR product was incubated with
2U BstUI restriction enzyme (CGCG) overnight at 37°C
before visualisation on a 2% agarose gel. The methyla-
tion status of ARHGAP20, CDC14B, CYP1B1, EYA2,
FAT1, GPR123, KNDC1, MYO10, PTGS2, SALL3,
TFAP2A, TFAP2C and TRPC4 was also determined by
bisulfite sequencing. Samples selected for bisulfite
sequencing were cloned in the pGEM-Teasy vector
according to manufacturer’s instructions. Up to 10 indi-
vidual colonies were chosen for colony PCR using the
primers specific for the pGEM-Teasy vector back bone,
forward 5’-TAATACGACTCACTATAGGG-3’ and
reverse 5’-ACACTATAGAATACTCAAGC-3’. Amplified
PCR products were then sequenced to ascertain the
methylation status of individual alleles and to determine
the methylation index (MI). The MI was calculated as a
percentage using the equation; number of CpG dinu-
cleotides methylated/total number of CpG dinucleotides
sequenced × 100.
Cell lines, 5azaDC treatment and RT-PCR
Leukemia cell lines were maintained in RPMI1640
(Sigma) supplemented with 10% FCS, 2 mM Gluta-
mine, 20 mM HEPES, 1 mM Sodium Pyruvate and
12.6 mM Glucose Monohydrate at 37°C, 5% CO2.C e l l s
were treated with 5 μM of the DNA demethylating
agent 5azaDC (Sigma) freshly prepared in ddH2Oa n d
filter-sterilised. The medium (including 5 μM 5azaDC)
was changed every day for 5 days. Cells were also trea-
ted on day 4 with 0.1 μM TSA for 24hrs. RNA was
prepared using RNA bee (AMS biotechnology) accord-
ing to manufacturers’ instructions. cDNA was gener-
ated from 1 μg total RNA using SuperScript III
(Invitrogen) and polyN primers. See additional file 7
for primer sequences. In all cases a GAPDH control
was included using conditions described previously [4].
Gene expression was detected by amplification from 50
ng of cDNA using 0.8 μM of each primer, 2 mM
MgCl2,0 . 2 5m Md N T P sa n d1 UF a s ts t a r tTaq
(Roche).
Statistical analysis
Statistical analysis was performed using Fisher’se x a c t
test or t test where appropriate. All reported P values
were two-sided and P < 0.05 was taken as statistically
significant.
Additional file 1: COBRA analysis in leukemia cell lines. Leukemia cell
lines analyzed for methylation using COBRA. U = undigested PCR
product, B = BstUI digested PCR product.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-44-
S1.PPT]
Additional file 2: additional genes. genes that are not frequently
methylated in ALL samples and/or are also methylated in control
samples.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-44-
S2.DOC]
Additional file 3: Statistical analysis of the GO-terms used.T h eP -
values for all the GO-terms used in Figure 5 using David annotation
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-44-
S3.DOC]
Additional file 4: COBRA analysis in epithelial cancer cell lines.
Methylation analysis in epithelial cancer cell lines. U = undigested PCR
product, B = BstUI digested PCR product. The cell lines labelled with *
correspond to either completely methylated or partially methylated cell
lines.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-44-
S4.PPT]
Additional file 5: Patient characteristics. Acute lymphoblastic leukemia
patient characteristics
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-44-
S5.DOC]
Additional file 6: COBRA primer sequences for the frequently
methylated genes. methylation primers used in this study
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-44-
S6.DOC]
Additional file 7: Expression primer sequences for the frequently
methylated genes. expression primers used in this study
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-44-
S7.DOC]
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